

INFORMATION DISCLOSURE STATEMENT


Applicant : Goddard, et al. (as amended)
App. No : 10/063,549
Filed : May 2, 2002
For : POLYPEPTIDES ENCODED BY A
NUCLEIC ACID OVEREXPRESSED
IN ESOPHAGEAL AND KIDNEY
TUMOR (as amended)
Examiner : Patricia Ann Duffy
Art Unit : 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 23, 2005

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 45 references to be considered by the Examiner. Also enclosed are 31 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note that reference No. 1 (Jacobs) is only being cited to correct a typographical error in the IDS which was filed September 6, 2002.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 23, 2005

By: 

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

06/27/2005 EAREGAY1 00000111 10063549

01 FC:1806

180.00 UP

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,549
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al. (as amended)
Art Unit	1645
Examiner	Patricia Ann Duffy
Attorney Docket No.	GNE.3230R1C34

(Multiple sheets used when necessary)

SHEET 1 OF 3

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,536,637	07-16-1996	Jacobs
	2	6,025,156	02-15-2000	Gwynn, et al.
	3	6,124,433	09-26-2000	Falb, et al.
	4	6,156,500	12-05-2000	Falb, Dean
	5	6,162,604	12-19-2000	Jacob, Chaim O.
	6	6,228,582	05-08-2001	Rodier, et al.
	7	6,395,306	05-28-2002	Cui, et al.
	8	6,414,117	07-02-2002	Levinson, D. A.
	9	6,465,185	10-15-2002	Goldfine, et al.
	10	6,498,235	12-24-2002	Sheppard, et al.
	11	6,562,343	05-13-2003	Levinson, D. A.
	12	6,645,499	11-11-2003	Lal, et al.
	13	6,730,502	05-04-2004	Van Hijum, et al.
	14	6,737,522	05-18-2004	Sundick, et al.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	18	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. <i>Molecular & Cellular Proteomics</i> 1.4, 304-313.	
	19	Database Search, DNA Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI]	
	20	Database Search, Protein Sequence Alignments [BLASTN 2.2.1[July-12-2001], NCBI]	
	21	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , Vol. 15, No. 16, pp. 4392-4401.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,549
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al. (as amended)
Art Unit	1645
Examiner	Patricia Ann Duffy
Attorney Docket No.	GNE.3230R1C34

(Multiple sheets used when necessary)

SHEET 2 OF 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	22	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C β II Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research</i> , Vol. 61, pp.1375-1381.	
	23	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	24	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	25	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	26	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	27	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	28	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	29	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , Vol. 19, pp. 1862- 1871.	
	30	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. <i>Journal of Proteome Research</i> , Vol. 2, pp. 405-412.	
	31	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	32	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	33	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, <i>National Academy of Sciences of the United States of America</i> , Vol. 83, No. 11, pp. 4049-4052	
	34	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	35	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	36	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	37	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	38	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research</i> , Vol. 29, No e22, pp.1-8.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No.	10/063,549
Filing Date	May 2, 2002
First Named Inventor	Goddard, et al. (as amended)
Art Unit	1645
Examiner	Patricia Ann Duffy
Attorney Docket No.	GNE.3230R1C34

Multiple sheets used when necessary)

SHEET 3 OF 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	39	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	40	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	41	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , Vol.5: pp. 411-421.	
	42	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	43	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	44	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	45	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1785917_1
062305

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.